<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">FsHtbKLhsmB5XxnMnxRcS5b</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2012000100006</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(12)09800106</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2011005000121</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Intera&#231;&#227;o entre as vias de sinaliza&#231;&#227;o de receptores serotonin&#233;rgicos e &#914;-adren&#233;rgicos em art&#233;ria femoral de ratos</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Delbin</surname>
            <given-names>Maria Andr&#233;ia</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Silva</surname>
            <given-names>Alexandre S&#233;rgio</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Antunes</surname>
            <given-names>Edson</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zanesco</surname>
            <given-names>Angelina</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date date-type="collection" publication-format="electronic">
        <month>01</month>
        <year>2012</year>
      </pub-date>
      <volume>98</volume>
      <issue>1</issue>
      <fpage>29</fpage>
      <lpage>34</lpage>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>04</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>30</day>
          <month>06</month>
          <year>2011</year>
        </date>
        <date date-type="rev-recd">
          <day>29</day>
          <month>06</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A doen&#231;a coron&#225;ria tem sido amplamente estudada em pesquisas cardiovasculares. No entanto, pacientes com doen&#231;a arterial perif&#233;rica (DAP) t&#234;m piores resultados em compara&#231;&#227;o &#224;queles com doen&#231;a arterial coronariana. Portanto, os estudos farmacol&#243;gicos com art&#233;ria femoral s&#227;o altamente relevantes para a melhor compreens&#227;o das respostas cl&#237;nicas e fisiopatol&#243;gicas da DAP. OBJETIVO: Avaliar as propriedades farmacol&#243;gicas dos agentes contr&#225;teis e relaxantes na art&#233;ria femoral de ratos. M&#201;TODOS: As curvas de resposta de concentra&#231;&#227;o &#224; fenilefrina contr&#225;til (FC) e &#224; serotonina (5-HT) e os agentes relaxantes isoproterenol (ISO) e forskolina foram obtidos na art&#233;ria femoral de ratos isolada. Para as respostas ao relaxamento, os tecidos foram contra&#237;dos com FC ou 5-HT. RESULTADOS: A pot&#234;ncia de classifica&#231;&#227;o na art&#233;ria femoral foi de 5-HT &gt; FC para as respostas contr&#225;teis. Em tecidos contra&#237;dos com 5-HT, as respostas de relaxamento ao isoproterenol foram praticamente abolidas em compara&#231;&#227;o aos tecidos contra&#237;dos com FC. A forskolina, um estimulante da adenilil ciclase, restaurou parcialmente a resposta de relaxamento ao ISO em tecidos contra&#237;dos com 5-HT. CONCLUS&#195;O: Ocorre uma intera&#231;&#227;o entre as vias de sinaliza&#231;&#227;o dos receptores &#946;-adren&#233;rgicos e serotonin&#233;rgicos na art&#233;ria femoral. Al&#233;m disso, esta pesquisa fornece um novo modelo para estudar as vias de sinaliza&#231;&#227;o serotonin&#233;rgicas em condi&#231;&#245;es normais e patol&#243;gicas que podem ajudar a compreender os resultados cl&#237;nicos na DAP.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Doen&#231;a arterial perif&#233;rica</kwd>
        <kwd>art&#233;ria femoral</kwd>
        <kwd>receptores adren&#233;rgicos</kwd>
        <kwd>receptores adren&#233;rgicos</kwd>
        <kwd>receptores de serotonina</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>15</day>
        <month>12</month>
        <year>2011</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>Intera&#231;&#227;o entre as vias de sinaliza&#231;&#227;o de receptores serotonin&#233;rgicos e </bold>
      <bold>&#914;</bold>
      <bold>-adren&#233;rgicos em art&#233;ria femoral de ratos</bold>
    </p>
    <p>
      <bold>Maria Andr&#233;ia Delbin; Alexandre S&#233;rgio Silva; Edson Antunes; Angelina Zanesco</bold>
    </p>
    <p><sup>I</sup>Universidade Estadual Paulista J&#250;lio de Mesquita Filho (UNESP), S&#227;o Paulo, SP</p>
    <p><sup>II</sup>Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brasil</p>
    <p>
      <xref ref-type="corresp" rid="corresp">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> A doen&#231;a coron&#225;ria tem sido amplamente estudada em pesquisas cardiovasculares. No entanto, pacientes com doen&#231;a arterial perif&#233;rica (DAP) t&#234;m piores resultados em compara&#231;&#227;o &#224;queles com doen&#231;a arterial coronariana. Portanto, os estudos farmacol&#243;gicos com art&#233;ria femoral s&#227;o altamente relevantes para a melhor compreens&#227;o das respostas cl&#237;nicas e fisiopatol&#243;gicas da DAP.</p>
    <p><bold>OBJETIVO:</bold> Avaliar as propriedades farmacol&#243;gicas dos agentes contr&#225;teis e relaxantes na art&#233;ria femoral de ratos.</p>
    <p><bold>M&#201;TODOS:</bold> As curvas de resposta de concentra&#231;&#227;o &#224; fenilefrina contr&#225;til (FC) e &#224; serotonina (5-HT) e os agentes relaxantes isoproterenol (ISO) e forskolina foram obtidos na art&#233;ria femoral de ratos isolada. Para as respostas ao relaxamento, os tecidos foram contra&#237;dos com FC ou 5-HT.</p>
    <p><bold>RESULTADOS:</bold> A pot&#234;ncia de classifica&#231;&#227;o na art&#233;ria femoral foi de 5-HT &gt; FC para as respostas contr&#225;teis. Em tecidos contra&#237;dos com 5-HT, as respostas de relaxamento ao isoproterenol foram praticamente abolidas em compara&#231;&#227;o aos tecidos contra&#237;dos com FC. A forskolina, um estimulante da adenilil ciclase, restaurou parcialmente a resposta de relaxamento ao ISO em tecidos contra&#237;dos com 5-HT.</p>
    <p><bold>CONCLUS&#195;O:</bold> Ocorre uma intera&#231;&#227;o entre as vias de sinaliza&#231;&#227;o dos receptores &#946;-adren&#233;rgicos e serotonin&#233;rgicos na art&#233;ria femoral. Al&#233;m disso, esta pesquisa fornece um novo modelo para estudar as vias de sinaliza&#231;&#227;o serotonin&#233;rgicas em condi&#231;&#245;es normais e patol&#243;gicas que podem ajudar a compreender os resultados cl&#237;nicos na DAP.</p>
    <p><bold>Palavras-chave:</bold> Doen&#231;a arterial perif&#233;rica, art&#233;ria femoral/fisiopatologia, receptores adren&#233;rgicos/alfa, receptores adren&#233;rgicos/beta, receptores de serotonina.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>Importante ramo da art&#233;ria il&#237;aca, a art&#233;ria femoral irriga os m&#250;sculos dos membros inferiores e os tecidos perif&#233;ricos, sendo um vaso sangu&#237;neo &#250;nico, com uma condu&#231;&#227;o longa, de alta resist&#234;ncia de fluxo e com uma relev&#226;ncia marcante para interven&#231;&#245;es m&#233;dicas<sup>1</sup>. De fato, aproximadamente 50% das doen&#231;as arteriais oclusivas (DAO) ocorrem na art&#233;ria femoral, podendo resultar em claudica&#231;&#227;o intermitente e isquemia cr&#237;tica do membro, com preju&#237;zo significativo &#224;s atividades di&#225;rias dos pacientes<sup>2</sup>. A incid&#234;ncia de doen&#231;a arterial perif&#233;rica (DAP) tem aumentado na popula&#231;&#227;o mundial, e consider&#225;veis esfor&#231;os t&#234;m sido envidados para melhorar as consequ&#234;ncias desfavor&#225;veis da interven&#231;&#227;o m&#233;dica no tratamento de longo prazo. Al&#233;m disso, fatores como tabagismo, dislipidemia, diabete melito, aterosclerose e idade avan&#231;ada t&#234;m sido implicados na patog&#234;nese da DAP<sup>3,4</sup>. Embora a maioria das pesquisas cardiovasculares tenha se voltado para a doen&#231;a coron&#225;ria, tais como avan&#231;os em interven&#231;&#245;es cir&#250;rgicas e descoberta de novas terapias farmacol&#243;gicas, os pacientes com DAP t&#234;m piores resultados em compara&#231;&#227;o &#224;queles com doen&#231;a da art&#233;ria coron&#225;ria<sup>5</sup>. Por essa raz&#227;o, os estudos farmacol&#243;gicos com art&#233;ria femoral s&#227;o altamente relevantes para a melhor compreens&#227;o das respostas cl&#237;nicas e fisiopatol&#243;gicas da DAP.</p>
    <p>Sabe-se que a serotonina (5-hidroxitriptamina, 5-HT) desempenha fun&#231;&#245;es biol&#243;gicas importantes no sistema cardiovascular, incluindo agrega&#231;&#227;o plaquet&#225;ria, bradicardia ou taquicardia, hipotens&#227;o ou hipertens&#227;o e vasodilata&#231;&#227;o ou vasoconstri&#231;&#227;o<sup>6,7</sup>. A diversidade das a&#231;&#245;es funcionais da 5-HT relaciona-se ao n&#250;mero de subtipos de receptores, bem como &#224; complexidade da via de sinaliza&#231;&#227;o envolvida nas respostas. A esse respeito, pelo menos 15 subtipos de receptores 5-HT t&#234;m sido caracterizados, sendo subdivididos em sete fam&#237;lias de receptores, de acordo com as propriedades farmacol&#243;gicas, as sequ&#234;ncias de amino&#225;cidos, a organiza&#231;&#227;o dos genes e as vias de acoplamento de segundo mensageiro<sup>8,9</sup>. As fam&#237;lias de receptores 5-HT1<sub>1</sub>, 5-HT<sub>2</sub>, 5-HT<sub>4</sub>, 5-HT<sub>5</sub>, 5-HT<sub>6</sub> e 5-HT<sub>7</sub> s&#227;o acopladas a G-prote&#237;nas, enquanto os receptores 5-HT3 s&#227;o canais i&#244;nicos associados &#224; 5-HT. Entre os receptores 5-HT, os subtipos 5-HT<sub>1</sub> e 5-HT<sub>2</sub> desempenham um papel importante na regula&#231;&#227;o do sistema cardiovascular, em que a fam&#237;lia do receptor 5-HT<sub>1</sub> est&#225; ligada principalmente &#224; prote&#237;na G inibit&#243;ria (Gi/o), que impede a forma&#231;&#227;o da adenosina monofosfato c&#237;clico (AMPc), enquanto a fam&#237;lia de receptores 5-HT2 &#233; acoplada preferencialmente a prote&#237;nas Gq/11, levando &#224; ativa&#231;&#227;o da via de sinaliza&#231;&#227;o IP3/PKC/citos&#243;lica [Ca<sup>2+</sup>]<sup>10</sup>. Tanto a fam&#237;lia de receptor 5-HT<sub>1</sub> quanto a de 5-HT<sub>2</sub> associam-se &#224; contra&#231;&#227;o do m&#250;sculo liso vascular e &#224; forma&#231;&#227;o de trombo<sup>9,11</sup>.</p>
    <p>A ativa&#231;&#227;o dos receptores &#945;- e &#946;-adren&#233;rgicos por catecolaminas tamb&#233;m produz uma s&#233;rie de respostas funcionais no sistema cardiovascular, incluindo respostas cronotr&#243;picas positivas e controle do t&#244;nus vascular<sup>12,13</sup>. A vasoconstri&#231;&#227;o mediada pelo receptor &#945;-adren&#233;rgico tem sido amplamente estudada em condi&#231;&#245;es normais e patol&#243;gicas<sup>14-16</sup>, mas poucos estudos avaliam a vasodilata&#231;&#227;o mediada pelos receptores &#946;-adren&#233;rgicos<sup>17,18</sup>. A esse respeito, pelo menos tr&#234;s subtipos de receptores &#946;-adren&#233;rgicos medeiam as respostas de relaxamento em tecidos vasculares e acoplam-se &#224; prote&#237;na Gs, levando &#224; ativa&#231;&#227;o da via de sinaliza&#231;&#227;o da prote&#237;na quinase (PK) dependente de AMPc<sup>19</sup>.</p>
    <p>As vias de sinaliza&#231;&#227;o dos receptores serotonin&#233;rgicos ou adren&#233;rgicos s&#227;o alvos para o tratamento das doen&#231;as cardiovasculares, incluindo insufici&#234;ncia card&#237;aca, hipertens&#227;o arterial, doen&#231;a coronariana e DAP<sup>4,20</sup>. Assim, os estudos farmacol&#243;gicos sobre pequenas art&#233;rias e as intera&#231;&#245;es entre as drogas, envolvendo as vias de sinaliza&#231;&#227;o dos receptores serotonin&#233;rgicos e adren&#233;rgicos, s&#227;o cruciais para o desenvolvimento de novos compostos em uma tentativa de melhorar a qualidade de vida de pacientes com doen&#231;as vasculares. Portanto, o objetivo deste estudo foi avaliar as propriedades farmacol&#243;gicas dos agentes contr&#225;teis (5-HT e fenileprina) e relaxantes (isoproterenol e forskolina) no segmento proximal da art&#233;ria femoral de ratos.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>Este estudo foi aprovado pelo Comit&#234; de &#201;tica da Faculdade de Medicina da Universidade de Campinas (UNICAMP), sob o protocolo n&#186; 1307-1.</p>
    <p>
      <bold>Animais</bold>
    </p>
    <p>Ratos Wistar machos (407, 6g) foram alojados individualmente em 26 &#177; 2 &#186;C, com alimentos e &#225;gua <italic>ad libitum</italic> e em 12h de luz (ciclo escuro e as luzes acesas &#224;s 6h). Al&#233;m disso, foram submetidos &#224; inala&#231;&#227;o de CO2, sacrificados por decapita&#231;&#227;o e sangrados.</p>
    <p>
      <bold>An&#233;is isolados da art&#233;ria femoral de ratos</bold>
    </p>
    <p>A art&#233;ria femoral foi rapidamente removida e colocada em solu&#231;&#227;o tamp&#227;o de Krebs-Henseleit, refrigerada com a seguinte composi&#231;&#227;o (mM): NaCl 118, KCl 4.7, KH<sub>2</sub>PO<sub>4</sub> 1.2, MgSO<sub>4</sub>.7H<sub>2</sub>O 1.17, CaCl<sub>2</sub>.2H<sub>2</sub>O 2.5, NaHCO<sub>3</sub> 25 e glucose 5.6. O segmento proximal da art&#233;ria femoral foi isolado, e dois an&#233;is (de aproximadamente 2 mm de comprimento) foram retirados e montados em uma c&#226;mara de &#243;rg&#227;os de 5 ml. Um mi&#243;grafo para grava&#231;&#227;o de for&#231;a isom&#233;trica (Danish Myo Technology, modelo 610m, Aarthus N, Dinamarca) foi acoplado a um sistema de aquisi&#231;&#227;o, com <italic>software</italic> espec&#237;fico (PowerLab 30/08, LabChart 7, ADInstruments, Sydney-NSW, Austr&#225;lia). A solu&#231;&#227;o de banho foi mantida a 37&#186;C e continuamente gaseificada com 95%-O<sub>2</sub> e 5%-CO<sub>2</sub>, com pH de 7,4. Os tecidos foram estabilizados por 60 minutos, sob uma tens&#227;o de repouso de 1 MN<sup>21</sup>.</p>
    <p>
      <bold>Curvas concentra&#231;&#227;o-resposta aos agentes contr&#225;teis</bold>
    </p>
    <p>Ap&#243;s o per&#237;odo de equil&#237;brio, os an&#233;is foram contra&#237;dos com KCl 80 mM, para verificar a viabilidade do tecido, e foram lavados com Krebs. Alem disso, foram contra&#237;dos com fenilefrina (FC, 1 mM) e relaxados com acetilcolina (ACH, 1 <italic>&#181;</italic>M), de modo a confirmar a integridade do endot&#233;lio. Os an&#233;is sem respostas contr&#225;teis ou relaxantes foram eliminados.</p>
    <p>A fim de avaliar as respostas contr&#225;teis mediadas por receptores serotonin&#233;rgicos e &#945;-adren&#233;rgicos, curvas cumulativas concentra&#231;&#227;o-resposta &#224; 5-hidroxitriptamina (5-HT: 1 nM - 100 mM) e &#224; fenilefrina (FC: 1 nM - 100 mM) foram constru&#237;das no segmento proximal dos an&#233;is da art&#233;ria femoral<sup>22</sup>.</p>
    <p>As curvas concentra&#231;&#227;o-resposta ao isoproterenol (1 nM - 10 mM) foram obtidas em tecidos contra&#237;dos com FC (1 mM) ou com 5-HT (10 mM), para analisar a intera&#231;&#227;o entre a ativa&#231;&#227;o dos receptores &#946;-adren&#233;rgicos e a dos receptores &#945;-adren&#233;rgicos ou serotonin&#233;rgicos. Tamb&#233;m realizamos curvas concentra&#231;&#227;o-resposta para o ativador adenilato ciclase e a forskolina (1 nM - 100 <italic>&#181;</italic>M) em an&#233;is femorais, com fins de determinar se as intera&#231;&#245;es medicamentosas podem acontecer em n&#237;vel do receptor ou em n&#237;veis superiores.</p>
    <p>Todos os dados de concentra&#231;&#227;o-resposta foram avaliados a fim de ajust&#225;-los em uma fun&#231;&#227;o log&#237;stica na f&#243;rmula: E = Emax/((1 + (10<sup>c</sup>/10<sup>x</sup>)<sup>n</sup>) + &#934;), em que E &#233; o efeito do basal acima; Emax &#233; a resposta m&#225;xima produzida pelo agonista; c &#233; o logaritmo da EC<sub>50</sub>, concentra&#231;&#227;o do agonista que produz metade do m&#225;ximo de resposta; x &#233; o logaritmo da concentra&#231;&#227;o do agonista; n &#233; um par&#226;metro de ajuste de curvas que define a inclina&#231;&#227;o da linha de resposta de concentra&#231;&#227;o; e &#934; &#233; a resposta observada na aus&#234;ncia do agonista acrescentado. A an&#225;lise de regress&#227;o n&#227;o linear foi utilizada para determinar os par&#226;metros Emax e log EC<sub>50</sub>, utilizando GraphPad Prism (GraphPad Software Inc., San Diego, CA), com a restri&#231;&#227;o de que &#934; = 0. As respostas para cada agonista s&#227;o demonstradas como a m&#233;dia &#177; EPM de pot&#234;ncia (pEC50) e resposta m&#225;xima (Emax). Os relaxamentos foram plotados como porcentagens das contra&#231;&#245;es induzidas pela FC ou 5-HT, e as respostas contr&#225;teis foram plotadas como porcentagem da concentra&#231;&#227;o induzida por KCl (80 mM).</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>Os dados s&#227;o expressos como m&#233;dia &#177; EPM de experimentos <italic>n</italic>. O teste <italic>t</italic> de Student pareado ou n&#227;o pareado foi realizado por meio de <italic>software</italic> espec&#237;fico (InStat, GraphPad Software, La Jolla, CA, EUA). Os valores de <italic>p</italic> inferiores a 0,05 foram considerados estatisticamente significativos.</p>
    <p>
      <bold>F&#225;rmacos</bold>
    </p>
    <p>Cloreto de acetilcolina, hidrocloreto de fenilefrina, 5-hidroxitriptamina, forskolina e isoproterenol foram adquiridos da Sigma Chemical Co. (St Louis, MO, EUA). </p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>
      <bold>Respostas contr&#225;teis</bold>
    </p>
    <p>Tanto a 5-HT quanto a FC produziram respostas contr&#225;teis dependentes da concentra&#231;&#227;o em an&#233;is de art&#233;ria femoral (<xref ref-type="fig" rid="aop11511_port_fig01">Figura 1A</xref>). A pot&#234;ncia da 5-HT foi significativamente maior em compara&#231;&#227;o &#224; FC &#945;1-agonista (cerca de 20 vezes) no segmento proximal da art&#233;ria femoral de ratos. N&#227;o foram encontradas diferen&#231;as nas respostas m&#225;ximas para ambos os agonistas. Esses dados est&#227;o resumidos na <xref ref-type="table" rid="aop11511_porttab01">Tabela 1</xref>.</p>
    <p content-type="asset">
      <table-wrap id="aop11511_porttab01">
        <graphic xlink:href="1678-4170-abc-98-01-0029-00121-gt01.jpg"/></table-wrap>
    </p>
    <p><fig id="aop11511_port_fig01"/>&#13;
&#160;&#13;
</p>
    <p>
      <fig id="aop11511_portfig01a">
        <graphic xlink:href="1678-4170-abc-98-01-0029-00121-gf01.jpg"/></fig>
    </p>
    <p>&#13;
  <fig id="aop11511_port_fig01xfig01b"/><fig id="aop11511_portfig01b"><graphic xlink:href="1678-4170-abc-98-01-0029-00121-gf02.jpg"/></fig></p>
    <p>&#13;
  <fig id="aop11511_port_fig01xfig01c"/><fig id="aop11511_portfig01c"><graphic xlink:href="1678-4170-abc-98-01-0029-00121-gf03.jpg"/></fig></p>
    <p>
      <bold>Respostas de relaxamento</bold>
    </p>
    <p>Em outro conjunto de experimentos, avaliamos as respostas de relaxamento para o isoproterenol agonista &#946;-adren&#233;rgico, em que os an&#233;is da art&#233;ria femoral foram contra&#237;dos com FC (10 <italic>&#181;</italic>M) ou 5-HT (1 <italic>&#181;</italic>M). Em an&#233;is contra&#237;dos com FC, o isoproterenol produziu respostas de relaxamento dependentes da concentra&#231;&#227;o. No entanto, em an&#233;is contra&#237;dos com 5-HT, o isoproterenol evocou uma resposta de relaxamento inferior em an&#233;is de art&#233;ria femoral em rela&#231;&#227;o aos an&#233;is pareados contra&#237;dos com FC (<xref ref-type="fig" rid="aop11511_port_fig01">Figura 1B</xref>). Para testar a hip&#243;tese de que tecidos contra&#237;dos com 5-HT afetavam o n&#237;vel dos receptores &#946;-adren&#233;rgicos ou os n&#237;veis superiores (via de sinaliza&#231;&#227;o), curvas de concentra&#231;&#227;o-resposta para o ativador da adenilil ciclase forskolina foram obtidas em an&#233;is de art&#233;ria femoral contra&#237;dos com FC (10 <italic>&#181;</italic>M) ou 5-HT (1 <italic>&#181;</italic>M). Em an&#233;is contra&#237;dos com FC, a forskolina produziu respostas de relaxamento dependentes da concentra&#231;&#227;o. Todavia, um deslocamento paralelo dextral, de cerca de nove vezes, foi observado nas curvas de concentra&#231;&#227;o-resposta para forskolina em tecidos contra&#237;dos com 5-HT, em compara&#231;&#227;o aos an&#233;is pareados da art&#233;ria femoral contra&#237;dos com FC (<a href="/img/revistas/abc/2011nahead/aop11511_port-fig01.html#fig01c" link-type="asset-not-found">Figura 1C</a>). N&#227;o foram encontradas diferen&#231;as nas respostas m&#225;ximas para o ativador da adenilil ciclase em contra&#231;&#227;o com dois agentes. Esses dados est&#227;o resumidos na <xref ref-type="table" rid="aop11511_porttab01">Tabela 1</xref>.</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Neste estudo, observou-se que a pot&#234;ncia de ordem de classifica&#231;&#227;o no segmento proximal da art&#233;ria femoral foi de 5-HT &gt; FC, para as respostas contr&#225;teis que podem refletir maior densidade de receptores serotonin&#233;rgicos ou elevada efic&#225;cia do mecanismo de via de sinaliza&#231;&#227;o nessa prepara&#231;&#227;o, em contraste com a via a jusante de receptores &#945;-adren&#233;rgicos/AMPc/PK. Curiosamente, um estudo anterior encontrou pot&#234;ncia de classifica&#231;&#227;o semelhante para a 5-HT em diferentes an&#233;is arteriais, incluindo os an&#233;is mesent&#233;ricos, caudais e basilares<sup>23</sup>. Al&#233;m disso, a pot&#234;ncia de 5-HT encontrada em nosso estudo para o segmento proximal na art&#233;ria femoral (6,86) mostrou-se intimamente relacionada aos resultados obtidos na art&#233;ria basilar (6,88), indicando que ambas as prepara&#231;&#245;es apresentam grandes semelhan&#231;as nas propriedades farmacol&#243;gicas. Al&#233;m disso, evid&#234;ncias cl&#237;nicas mostram que a DAP &#233; mais comum em pacientes com enxaqueca do que em pacientes n&#227;o acometidos pela cefaleia<sup>24,25</sup>. Ao todo, nossos dados mostram que a art&#233;ria femoral &#233; um interessante modelo para o estudo das vias de sinaliza&#231;&#227;o dos receptores serotonin&#233;rgicos em condi&#231;&#245;es normais e patol&#243;gicas, como diabete melito e aterosclerose.</p>
    <p>Neste estudo, tamb&#233;m descobrimos que os tecidos contra&#237;dos com 5-HT praticamente aboliram a resposta de relaxamento para o isoproterenol (10% de respostas m&#225;ximas), tendo sido parcialmente restaurados pela forskolina, um estimulante de a&#231;&#227;o direta da guanilato ciclase que ignora &#946;-adren&#233;rgicos. Portanto, nossos resultados mostram uma intera&#231;&#227;o entre as vias de sinaliza&#231;&#227;o dos receptores &#946;-adren&#233;rgicos e serotonin&#233;rgicos na art&#233;ria femoral. A esse respeito, um estudo anterior demonstrou uma intera&#231;&#227;o entre o receptor &#946;-adren&#233;rgico e a 5-HT1 na libera&#231;&#227;o de glutamato nos terminais do nervo cerebrocortical<sup>26</sup>. Assim, nossos dados refor&#231;am que o segmento proximal da art&#233;ria femoral &#233; um tecido vascular interessante para estudar os receptores de 5-HT e a complexa via de sinaliza&#231;&#227;o. No entanto, n&#227;o podemos determinar, a partir deste estudo, que o subtipo de receptor 5-HT medeia a resposta contr&#225;til ou os efetores de transdu&#231;&#227;o que contribuem para a supress&#227;o do relaxamento de media&#231;&#227;o do receptor &#946;-adren&#233;rgico na art&#233;ria femoral de ratos. Evid&#234;ncias indicam que a fam&#237;lia de receptores 5-HT1 &#233; fundamentalmente ligada &#224; Gi/o, prote&#237;na sens&#237;vel &#224; toxina pert&#250;ssis negativamente associada &#224; adenilil ciclase<sup>9</sup>. Por outro lado, a ativa&#231;&#227;o do receptor &#946;-adren&#233;rgico &#233; acoplada &#224; prote&#237;na Gs, que, por sua vez, leva &#224; ativa&#231;&#227;o da via de sinaliza&#231;&#227;o AMPc/PK no sistema cardiovascular<sup>19</sup>. Assim, a intera&#231;&#227;o antag&#244;nica entre os receptores 5-HT e &#946;-adren&#233;rgicos pode ocorrer no receptor acoplado &#224; prote&#237;na G, bem como no n&#237;vel dos substratos de PK, tendo em vista que a forskolina restaurou parcialmente a supress&#227;o do relaxamento de media&#231;&#227;o do receptor &#946;-adren&#233;rgico em an&#233;is da art&#233;ria femoral de ratos contra&#237;dos com 5-HT. O significado funcional desses dados pode estar relacionado &#224; incid&#234;ncia de doen&#231;a vascular e &#224; administra&#231;&#227;o de agonistas de 5-HT/bloqueadores de capta&#231;&#227;o de 5-HT em algumas doen&#231;as como enxaqueca e obesidade.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>Em conclus&#227;o, nossos dados mostraram claramente que ocorre uma intera&#231;&#227;o entre as vias de sinaliza&#231;&#227;o dos receptores &#946;-adren&#233;rgicos e serotonin&#233;rgicos em an&#233;is da art&#233;ria femoral de ratos. Al&#233;m disso, este estudo fornece uma perspectiva interessante para o estudo das vias de sinaliza&#231;&#227;o dos receptores serotonin&#233;rgicos em condi&#231;&#245;es normais e patol&#243;gicas, em uma tentativa de melhorar os resultados cl&#237;nicos em pacientes com DAP.</p>
    <p>
      <fn id="corresp" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Maria Andreia Delbin</p>
        <p> Av. 24A 1515, Bela Vista</p>
        <p> 13990000 - Rio Claro, S&#227;o Paulo, Brasil</p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="nadelbin@hotmail.com">nadelbin@hotmail.com</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 28/04/11; revisado recebido em 29/06/11; aceito em 30/06/11.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Mewissen MW. Stenting in the femoropopliteal arterial segment. Tech Vasc Interv Radiol. 2005;8(4):146-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Stenting in the femoropopliteal arterial segment</article-title>
          <source>Tech Vasc Interv Radiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>146</fpage>
          <lpage>9</lpage>
          <issue>4</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mewissen</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Schainfeld RM. Management of peripheral arterial disease and intermittent claudication. J Am Board Fam Pract. 2001;14(6):443-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Management of peripheral arterial disease and intermittent claudication</article-title>
          <source>J Am Board Fam Pract</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>443</fpage>
          <lpage>50</lpage>
          <issue>6</issue>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schainfeld</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Balzer JO, Scheinert D, Diebold T, Haufe M, Vogl TJ, Biamino G. Postinterventional transcutaneous suture of femoral artery access sites in patients with peripheral arterial occlusive disease: a study of 930 patients. Catheter Cardiovasc Interv. 2001;53(2):174-81.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Postinterventional transcutaneous suture of femoral artery access sites in patients with peripheral arterial occlusive disease: a study of 930 patients</article-title>
          <source>Catheter Cardiovasc Interv</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>174</fpage>
          <lpage>81</lpage>
          <issue>2</issue>
          <volume>53</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Balzer</surname>
              <given-names>JO</given-names>
            </name>
            <name>
              <surname>Scheinert</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Diebold</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Haufe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vogl</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Biamino</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Lumsden AB, Rice TW, Chen C, Zhou W, Lin PH, Bray P, et al. Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management. World J Surg. 2007; 31(4):695-704.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management</article-title>
          <source>World J Surg</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>695</fpage>
          <lpage>704</lpage>
          <issue>4</issue>
          <volume>31</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lumsden</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Rice</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Bray</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Mardikar HM, Mukherjee D. Current endovascular treatment of peripheral arterial disease. Prog Cardiovasc Nurs. 2007;22(1):31-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Current endovascular treatment of peripheral arterial disease</article-title>
          <source>Prog Cardiovasc Nurs</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>31</fpage>
          <lpage>7</lpage>
          <issue>1</issue>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mardikar</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Mukherjee</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav. 2002;71(4):533-54.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Molecular, pharmacological and functional diversity of 5-HT receptors</article-title>
          <source>Pharmacol Biochem Behav</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>533</fpage>
          <lpage>54</lpage>
          <issue>4</issue>
          <volume>71</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hoyer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hannon</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>GR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355-66.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The expanded biology of serotonin</article-title>
          <source>Annu Rev Med</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>355</fpage>
          <lpage>66</lpage>
          <volume>60</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Berger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>BL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Kaumann AJ, Levy FO. 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther. 2006;111(3):674-706.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>5-hydroxytryptamine receptors in the human cardiovascular system</article-title>
          <source>Pharmacol Ther</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>674</fpage>
          <lpage>706</lpage>
          <issue>3</issue>
          <volume>111</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kaumann</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>FO</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Hannon J, Hoyer D. Molecular biology of 5-HT receptors. Behav Brain Res. 2008;195(1):198-213.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Molecular biology of 5-HT receptors</article-title>
          <source>Behav Brain Res</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>198</fpage>
          <lpage>213</lpage>
          <issue>1</issue>
          <volume>195</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hannon</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hoyer</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Martin GR, Eglen RM, Hamblin MW, Hoyer D, Yocca F. The structure and signalling properties of 5-HT receptors: an endless diversity? Trends Pharmacol Sci. 1998;19(1):2-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The structure and signalling properties of 5-HT receptors: an endless diversity?</article-title>
          <source>Trends Pharmacol Sci</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>2</fpage>
          <lpage>4</lpage>
          <issue>1</issue>
          <volume>19</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Martin</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Eglen</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Hamblin</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Hoyer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Yocca</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Nagatomo T, Rashid M, Abul Muntasir H, Komiyama T. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther. 2004;104(1):59-81.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Functions of 5-HT2A receptor and its antagonists in the cardiovascular system</article-title>
          <source>Pharmacol Ther</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>59</fpage>
          <lpage>81</lpage>
          <issue>1</issue>
          <volume>104</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nagatomo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Rashid</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Abul Muntasir</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Komiyama</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Insel PA. Adrenergic receptors: evolving concepts on structure and function. Am J Hypertens. 1989;2(3 Pt 2):112S-8S.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Adrenergic receptors: evolving concepts on structure and function</article-title>
          <source>Am J Hypertens</source>
          <date>
            <year>1989</year>
          </date>
          <fpage>112S</fpage>
          <lpage>8S</lpage>
          <issue>3</issue>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Insel</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac beta-adrenergic receptors, and heart failure. Circulation. 2000;101(14):1634-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Catecholamines, cardiac beta-adrenergic receptors, and heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1634</fpage>
          <lpage>7</lpage>
          <issue>14</issue>
          <volume>101</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lefkowitz</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Rockman</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Zanesco A, De-Moraes S. Effect of acute footshock stress on the responsiveness of the isolated rat tail artery to phenylephrine and epinephrine. Braz J Med Biol Res. 1992;25(1):63-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of acute footshock stress on the responsiveness of the isolated rat tail artery to phenylephrine and epinephrine</article-title>
          <source>Braz J Med Biol Res</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>63</fpage>
          <lpage>6</lpage>
          <issue>1</issue>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zanesco</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>De-Moraes</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Docherty JR. Subtypes of functional alpha1- and alpha2-adrenoceptors. Eur J Pharmacol. 1998;361(1):1-15.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Subtypes of functional alpha1- and alpha2-adrenoceptors</article-title>
          <source>Eur J Pharmacol</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1</fpage>
          <lpage>15</lpage>
          <issue>1</issue>
          <volume>361</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Docherty</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Rocha ML, Kihara AH, Davel AP, Britto LR, Rossoni LV, Bendhack LM. Blood pressure variability increases connexin expression in the vascular smooth muscle of rats. Cardiovasc Res. 2008;80(1):123-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Blood pressure variability increases connexin expression in the vascular smooth muscle of rats</article-title>
          <source>Cardiovasc Res</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>123</fpage>
          <lpage>30</lpage>
          <issue>1</issue>
          <volume>80</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rocha</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Kihara</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Davel</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Britto</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Rossoni</surname>
              <given-names>LV</given-names>
            </name>
            <name>
              <surname>Bendhack</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Chiba S, Tsukada M. Vascular responses to beta-adrenoceptor subtype-selective agonists with and without endothelium in rat common carotid arteries. J Auton Pharmacol. 2001;21(1):7-13.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Vascular responses to beta-adrenoceptor subtype-selective agonists with and without endothelium in rat common carotid arteries</article-title>
          <source>J Auton Pharmacol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>7</fpage>
          <lpage>13</lpage>
          <issue>1</issue>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chiba</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tsukada</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Matsushita M, Tanaka Y, Koike K. Studies on the mechanisms underlying beta-adrenoceptor-mediated relaxation of rat abdominal aorta. J Smooth Muscle Res. 2006;42(6):217-25.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Studies on the mechanisms underlying beta-adrenoceptor-mediated relaxation of rat abdominal aorta</article-title>
          <source>J Smooth Muscle Res</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>217</fpage>
          <lpage>25</lpage>
          <issue>6</issue>
          <volume>42</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Matsushita</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Koike</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev. 2001;53(2):319 56.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Vascular adrenoceptors: an update</article-title>
          <source>Pharmacol Rev</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>319 56</fpage>
          <issue>2</issue>
          <volume>53</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Guimaraes</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Moura</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Mbaki Y, Ramage AG. Investigation of the role of 5-HT2 receptor subtypes in the control of the bladder and the urethra in the anaesthetized female rat. Br J Pharmacol. 2008;155(3):343-56.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Investigation of the role of 5-HT2 receptor subtypes in the control of the bladder and the urethra in the anaesthetized female rat</article-title>
          <source>Br J Pharmacol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>343</fpage>
          <lpage>56</lpage>
          <issue>3</issue>
          <volume>155</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mbaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ramage</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Drescher W, Varoga D, Liebs TR, Lohse J, Herdegen T, Hassenpflug Jl, et al. Femoral artery constriction by norepinephrine is enhanced by methylprednisolone in a rat model. J Bone Joint Surg Am. 2006;8(Suppl. 3):162-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Femoral artery constriction by norepinephrine is enhanced by methylprednisolone in a rat model</article-title>
          <source>J Bone Joint Surg Am</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>162</fpage>
          <lpage>6</lpage>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Drescher</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Varoga</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Liebs</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Lohse</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Herdegen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hassenpflug</surname>
              <given-names>Jl</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Van Rossum JM. Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn Ther. 1963;143:299-330.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cumulative dose-response curves: II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters</article-title>
          <source>Arch Int Pharmacodyn Ther</source>
          <date>
            <year>1963</year>
          </date>
          <fpage>299</fpage>
          <lpage>330</lpage>
          <volume>143</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Van Rossum</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Gupta S, Mehrotra S, Villal&#243;n C, De Vries R, Garrelds I, Saxena P, et al. Effects of female sex hormones on responses to CGRP, acetylcholine, and 5-HT in rat isolated arteries. Headache. 2007;47(4):564-75.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of female sex hormones on responses to CGRP, acetylcholine, and 5-HT in rat isolated arteries</article-title>
          <source>Headache</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>564</fpage>
          <lpage>75</lpage>
          <issue>4</issue>
          <volume>47</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gupta</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mehrotra</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Villal&#243;n</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>De Vries</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Garrelds</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Saxena</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Halloul Z, Meyer F, Lippert H, Buerger T. Ergotamine-induced acute vascular insufficiency of the lower limb--a case report. Angiology. 2001;52(3):217-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ergotamine-induced acute vascular insufficiency of the lower limb--a case report</article-title>
          <source>Angiology</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>217</fpage>
          <lpage>21</lpage>
          <issue>3</issue>
          <volume>52</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Halloul</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lippert</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Buerger</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Jurno ME, Chevtchouk L, Nunes AA, de Rezende DF, Jevoux Cda C, de Souza JA, et al. Ankle-brachial index, a screening for peripheral obstructive arterial disease, and migraine - a controlled study. Headache. 2010;50(4):626-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ankle-brachial index, a screening for peripheral obstructive arterial disease, and migraine - a controlled study</article-title>
          <source>Headache</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>626</fpage>
          <lpage>30</lpage>
          <issue>4</issue>
          <volume>50</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Jurno</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Chevtchouk</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Nunes</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>de Rezende</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Jevoux Cda</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>de Souza</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Wang SJ, Coutinho V, Sihra TS. Presynaptic cross-talk of beta-adrenoreceptor and 5-hydroxytryptamine receptor signalling in the modulation of glutamate release from cerebrocortical nerve terminals. Br J Pharmacol. 2002;137(8):1371-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Presynaptic cross-talk of beta-adrenoreceptor and 5-hydroxytryptamine receptor signalling in the modulation of glutamate release from cerebrocortical nerve terminals</article-title>
          <source>Br J Pharmacol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1371</fpage>
          <lpage>9</lpage>
          <issue>8</issue>
          <volume>137</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Coutinho</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Sihra</surname>
              <given-names>TS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Interaction between serotoninergic-and &#946;-adrenergic receptors signaling pathways in rat femoral artery</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Coronary heart disease has been widely studied in cardiovascular research. However, patients with peripheral artery disease (PAD) have worst outcomes compared to those with coronary artery disease. Therefore, pharmacological studies using femoral artery are highly relevant for a better understanding of the pathophysiologic responses of the PAD. OBJECTIVE: The aim of this study was to evaluate the pharmacologic properties of the contractile and relaxing agents in rat femoral artery. METHODS: Concentration response curves to the contractile phenylephrine (PE) and serotonin (5-HT) and the relaxing agents isoproterenol (ISO) and forskolin were obtained in isolated rat femoral artery. For relaxing responses, tissues were precontracted with PE or 5-HT. RESULTS: The order rank potency in femoral artery was 5-HT &gt; PE for contractile responses. In tissues precontracted with 5-HT, relaxing responses to isoproterenol was virtually abolished as compared to PE-contracted tissues. Forskolin, a stimulant of adenylyl cyclase, partially restored the relaxing response to ISO in 5-HT-precontracted tissues. CONCLUSION: An interaction between &#946;-adrenergic- and serotoninergic- receptors signaling pathway occurs in femoral artery. Moreover, this study provides a new model to study serotoninergic signaling pathway under normal and pathological conditions which can help understanding clinical outcomes in the PAD.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Peripheral arterial disease</kwd>
        <kwd>femoral artery</kwd>
        <kwd>receptors, adrenergic</kwd>
        <kwd>receptors, adrenergic</kwd>
        <kwd>receptors, serotonin</kwd>
        <kwd>arteria femoral</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Interaction between serotoninergic-and </bold>
          </label>
          <p>
            <bold>&#946;</bold>
          </p>
          <p>
            <bold>-adrenergic receptors signaling pathways in rat femoral artery</bold>
          </p>
        </fn>
      </p>
      <p>
        <bold>Maria Andr&#233;ia Delbin; Alexandre S&#233;rgio Silva; Edson Antunes; Angelina Zanesco</bold>
      </p>
      <p><sup>I</sup>Universidade Estadual Paulista J&#250;lio de Mesquita Filho (UNESP), S&#227;o Paulo, SP</p>
      <p><sup>II</sup>Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brasil</p>
      <p>Mailing Address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Coronary heart disease has been widely studied in cardiovascular research. However, patients with peripheral artery disease (PAD) have worst outcomes compared to those with coronary artery disease. Therefore, pharmacological studies using femoral artery are highly relevant for a better understanding of the pathophysiologic responses of the PAD.</p>
      <p><bold>OBJECTIVE:</bold> The aim of this study was to evaluate the pharmacologic properties of the contractile and relaxing agents in rat femoral artery.</p>
      <p><bold>METHODS:</bold> Concentration response curves to the contractile phenylephrine (PE) and serotonin (5-HT) and the relaxing agents isoproterenol (ISO) and forskolin were obtained in isolated rat femoral artery. For relaxing responses, tissues were precontracted with PE or 5-HT.</p>
      <p><bold>RESULTS:</bold> The order rank potency in femoral artery was 5-HT &gt; PE for contractile responses. In tissues precontracted with 5-HT, relaxing responses to isoproterenol was virtually abolished as compared to PE-contracted tissues. Forskolin, a stimulant of adenylyl cyclase, partially restored the relaxing response to ISO in 5-HT-precontracted tissues.</p>
      <p><bold>CONCLUSION:</bold> An interaction between &#946;-adrenergic- and serotoninergic- receptors signaling pathway occurs in femoral artery. Moreover, this study provides a new model to study serotoninergic signaling pathway under normal and pathological conditions which can help understanding clinical outcomes in the PAD. </p>
      <p><bold>Keywords:</bold> Peripheral arterial disease, femoral artery/physiopathology, receptors, adrenergic/alpha, receptors, adrenergic/beta, receptors, serotonin.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Femoral artery is an important branch of the iliac artery that irrigates the lower limb skeletal muscles and peripheral tissues and it is a unique blood vessel with a long conduction, high-flow resistance and a striking relevance for medical interventions<sup>1</sup>. Indeed, approximately 50% of all athero-occlusive disease takes place in the femoral artery which can result in intermittent claudication and critical limb ischemia with significant impairment of patients' daily activity<sup>2</sup>. The incidence of peripheral artery occlusive disease (PAD) has been increasing in the world population and considerable efforts have been made to improve the poor interventional outcomes in long-term treatment. Moreover, factors such as smoking, dyslipidemia, diabetes mellitus, atherosclerosis and advancing age have been implicated in the pathogenesis of the PAD<sup>3,4</sup>. Although most of the many cardiovascular researches have been focused on the coronary heart disease such as advances in surgical interventions and discovery of new pharmacological therapies, patients with PAD have worst outcomes compared to those with coronary artery disease<sup>5</sup>. For that reason, pharmacological studies using femoral artery are highly relevant for a better understanding of clinical and pathophysiologic responses of the PAD.</p>
      <p>It is well known that serotonin (5-hydroxytryptamine, 5-HT) plays important biologic functions in the cardiovascular system including platelet aggregation, bradycardia or tachycardia, hypotension or hypertension, and vasodilatation or vasoconstriction<sup>6,7</sup>. The diversity of the functional actions of the 5-HT relates to its receptor subtypes number as well as to the complexity of the signaling pathway involved in their responses. In this regard, at least fifteen 5-HT receptor subtypes have been characterized which are subdivided into seven receptor families according to their pharmacologic properties, amino acid sequences, gene organization, and second messenger coupling pathways<sup>8,9</sup>. The 5-HT<sub>1</sub>, 5-HT<sub>2</sub>, 5-HT<sub>4</sub>, 5-HT<sub>5</sub>, 5-HT<sub>6</sub>, and 5-HT<sub>7</sub> receptor families are coupled to G-proteins, whereas the 5-HT3 receptors are 5-HT-gated ion channels. Among the 5-HT receptors, 5-HT<sub>1</sub> and 5-HT<sub>2 </sub>receptors subtypes play an important role in the cardiovascular system regulation where 5-HT<sub>1 </sub>receptor family is mostly linked to Gi/o protein, which inhibit cAMP formation, whereas 5-HT<sub>2 </sub>receptors family is coupled preferentially via Gq/11 protein leading to the activation of IP3/PKC/cytosolic [Ca<sup>2+</sup>] signaling pathway<sup>10</sup>. Both 5-HT<sub>1</sub> and 5-HT<sub>2</sub> receptor families have been associated with contraction of vascular smooth muscle and thrombus formation<sup>9,11</sup>.</p>
      <p>The activation of &#945;- and &#946;-adrenergic receptors by catecholamines also produces a number of functional responses in the cardiovascular system including positive chronotropic responses and vascular tone control<sup>12,13</sup>. The &#945;-adrenergic receptor-mediated vasoconstriction has been widely studied under normal and pathological conditions<sup>14-16</sup>, but few studies evaluate the &#946;-adrenergic receptors-mediated vasodilatation<sup>17,18</sup>. In this regard, at least three &#946;-adrenergic receptors subtypes mediate the relaxation responses in vascular tissues, which are coupled to Gs protein leading to the activation of cAMP-dependent protein kinase (PKA) signaling pathway<sup>19</sup>.</p>
      <p>Either serotoninergic or adrenergic receptors signaling pathways are targets for the treatment of the cardiovascular diseases including heart failure, arterial hypertension, coronary artery disease and PAD<sup>4,20</sup>. Thus, pharmacological studies regarding small arteries and the interactions between drugs involving both serotoninergic and adrenergic receptor signaling pathways are crucial for developing new compounds in a attempt to improve the quality of life of patients with vascular disease. Therefore, the objective of this study was to evaluate the pharmacologic properties of the contractile (5-HT and phenylephrine) and relaxing agents (isoproterenol and forskolin) in the proximal segment of rat femoral artery. </p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>
        <bold>Animals</bold>
      </p>
      <p>This study was approved (protocol: 1307-1) by the Ethical Committee of the Medical School of Universidade de Campinas (UNICAMP). They were individually housed at 26 &#177; 2 &#186;C with food and water delivered ad libitum on a 12 h light: dark cycle with the lights turned on at 6:00 a.m. Male Wistar rats (407&#177;6g) were stunned by inhalation of CO<sub>2</sub>, euthanized by decapitation, and exsanguinated. </p>
      <p>
        <bold>Rat isolated femoral artery rings </bold>
      </p>
      <p>The femoral artery was quickly removed and placed in chilled Krebs-Henseleit buffer with the following composition (mM): NaCl 118, KCl 4.7, KH<sub>2</sub>PO<sub>4</sub> 1.2, MgSO<sub>4</sub>.7H<sub>2</sub>O 1.17, CaCl<sub>2</sub>.2H<sub>2</sub>O 2.5, NaHCO<sub>3</sub> 25 and glucose 5.6. The proximal segment of the femoral artery was isolated and two rings (approximately 2 mm length) were taken and mounted in a 5 ml organ chamber. A wire myograph for isometric force recording (Danish Myo Technology, model 610M, Aarthus N, Denmark) coupled with an acquisition system with specific software (PowerLab 8/30, LabChart 7, ADInstruments, Sydney-NSW, Austr&#225;lia). The bathing solution was maintained at 37&#186;C and continuously gassed with 95%-O<sub>2</sub> and 5%-CO<sub>2, </sub>with of pH 7.4. The tissues were allowed to equilibrate for 60 minutes under a resting tension of 1 mN<sup>21</sup>.</p>
      <p>
        <bold>Concentration-response curves to contractile agents</bold>
      </p>
      <p>Following the equilibration period, the rings were precontracted with KCl 80 mM to verify the tissue viability and washed with Krebs. The rings were precontracted with phenylephrine (PE: 1 <italic>&#181;</italic>M) and relaxed to acetylcholine (ACH: 1 <italic>&#181;</italic>M) to confirm the endothelium integrity. Rings lacking contractile or relaxing responses were disposed of.</p>
      <p>To evaluate the contractile responses mediated by serotoninergic and &#945;-adrenergic receptors, cumulative concentration-response curves to 5-hydroxytryptamine (5-HT: 1 nM - 100 <italic>&#181;</italic>M) and phenylephrine (PE: 1 nM - 100 <italic>&#181;</italic>M) were constructed in the proximal segment of the femoral artery rings<sup>22</sup>.</p>
      <p>Concentration-response curves to isoproterenol (1 nM - 10 mM) were obtained in precontracted tissues with PE (1 <italic>&#181;</italic>M) or 5-HT (10 <italic>&#181;</italic>M) to further analyze the interactions between &#946;-adrenergic receptors activation and &#945;-adrenergic or serotoninergic receptors. We also performed concentration-response curves to adenylyl cyclase activator, forskolin (1 nM - 100 <italic>&#181;</italic>M) in femoral rings, to determine whether the drug interactions could be at receptor level or beyond.</p>
      <p>All the concentration-response data were evaluated in order to fit into a logistics function in the formula:</p>
      <p>E = Emax/((1 + (10<sup>c</sup>/10<sup>x</sup>)<sup>n</sup>) + &#934;)</p>
      <p>where E is the effect of above basal; Emax is the maximum response produced by the agonist; c is the logarithm of the EC<sub>50</sub>, the concentration of the agonist that produces half-maximal response; x is the logarithm of the concentration of the agonist; the exponential term, n is a curve-fitting parameter that defines the slope of the concentration response line, and &#934; is the response observed in the absence of the agonist added. Nonlinear regression analysis was used to determine the parameters Emax and log EC<sub>50</sub>, by using GraphPad Prism (GraphPad Software Inc., San Diego, CA) with the constraint that &#934; = 0. The responses for each agonist are shown as the mean &#177; SEM of potency (pEC<sub>50</sub>) and maximal response (Emax). The relaxations were plotted as percentages of the contractions induced by PE or 5-HT and the contractile responses were plotted as percentage of the concentration induced by KCl (80 mM).</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>The data are expressed as mean &#177; SEM of <italic>n</italic> experiments. Paired or unpaired Student's <italic>t</italic> test was performed using specific software (InStat, GraphPad Software. La Jolla-CA, USA). Values of p &lt; 0.05 were considered statistically significant.</p>
      <p>
        <bold>Drugs</bold>
      </p>
      <p>Acetylcholine chloride, phenylephrine hydrochloride, 5-hydroxytryptamine, forskolin and isoproterenol were purchased from Sigma Chemical Co. (St Louis, MO, USA). </p>
      <p>
        <bold>Results</bold>
      </p>
      <p>
        <bold>Contractile responses </bold>
      </p>
      <p>Both 5-HT and PE produced concentration-dependent contractile responses in femoral artery rings (<xref ref-type="fig" rid="aop11511_ing_fig01-body2">Figure 1A</xref>). The potency of 5-HT was significantly greater compared to the &#945;<sub>1</sub>-agonist PE, approximately 20-fold, in the proximal segment of rat femoral artery. No differences were found in the maximal responses for both agonists. The data are summarized in <xref ref-type="table" rid="aop11511_ingtab01-body2">Table 1</xref>. </p>
      <p content-type="asset">
        <table-wrap id="aop11511_ingtab01-body2">
          <graphic xlink:href="1678-4170-abc-98-01-0029-00121-gt01-en.jpg"/></table-wrap>
      </p>
      <p><fig id="aop11511_ing_fig01-body2"/>&#13;
&#160;&#13;
</p>
      <p>
        <fig id="aop11511_ingfig01a-body2">
          <graphic xlink:href="1678-4170-abc-98-01-0029-00121-gf01-en.jpg"/></fig>
      </p>
      <p>&#13;
  <fig id="aop11511_ing_fig01xfig01b-body2"/><fig id="aop11511_ingfig01b-body2"><graphic xlink:href="1678-4170-abc-98-01-0029-00121-gf02-en.jpg"/></fig></p>
      <p>&#13;
  <fig id="aop11511_ing_fig01xfig01c-body2"/><fig id="aop11511_ingfig01c-body2"><graphic xlink:href="1678-4170-abc-98-01-0029-00121-gf03-en.jpg"/></fig></p>
      <p>
        <bold>Relaxing responses</bold>
      </p>
      <p>In another set of experiments, we evaluate the relaxing responses to &#946;-adrenergic agonist isoproterenol where femoral artery rings were precontracted with PE (10 <italic>&#181;</italic>M) or 5-HT (1 <italic>&#181;</italic>M). In PE-precontracted rings, isoproterenol produced concentration-dependent relaxation responses. However, in 5-HT-precontracted rings, isoproterenol evoked a slight relaxing response in femoral artery rings compared to its paired PE-precontracted rings (<xref ref-type="fig" rid="aop11511_ing_fig01-body2">Figure 1B</xref>). To further test the hypothesis that 5-HT-precontracted tissues were affecting at the level of &#946;-adrenergic receptor or beyond (signaling pathway), concentration-response curves to the adenylyl cyclase activator forskolin were obtained in femoral artery rings precontracted with PE (10 <italic>&#181;</italic>M) or 5-HT (1 <italic>&#181;</italic>M). In PE-precontracted rings, forskolin produced concentration-dependent relaxation responses. However, a parallel dextral displacement, approximately 9-fold, was observed in the concentration-response curves to forskolin in 5-HT precontracted tissues as compared to its paired PE-precontracted femoral artery rings (<xref ref-type="fig" rid="aop11511_ing_fig01-body2">Figure 1C</xref>). No differences were found in the maximal responses for adenylyl cyclase activator precontracting with both agents. All data are summarized in <xref ref-type="table" rid="aop11511_ingtab01-body2">Table 1</xref>.</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>In this study, we observed that the order rank potency in the proximal segment of femoral artery was 5-HT &gt; PE for contractile responses that may reflect a greater density of serotoninergic receptors and/or high effectiveness of its signaling pathway mechanism in this preparation compared to the activation of &#945;-adrenergic receptor/cAMP/PKA downstream pathway. Interestingly, a previous study found a similar rank potency for 5-HT in different artery rings including mesenteric, caudal and basilar<sup>23</sup>. Moreover, the potency for 5-HT found in our study for proximal segment in the femoral artery (6.86) was closely related to those obtained in the basilar artery (6.88) indicating that both preparations present great similarities in pharmacologic properties. Interestingly, clinical evidences have shown that PAD is more common in migraineurs than in controls<sup>24,25</sup>. Altogether, our data showed that femoral artery is an interestingly model to study serotoninergic receptor signaling pathway under normal and pathological conditions such as diabetes mellitus and atherosclerosis.</p>
      <p>In this study, we have also found that precontracted tissues with 5-HT virtually abolished the relaxing responses to isoproterenol (10% of maximal responses) that was partially restored by forskolin, a direct-acting stimulant of adenylyl cyclase that bypass &#946;-adrenergic receptors. Therefore, our findings showed an interaction between &#946;-adrenergic- and serotoninergic- receptors signaling pathway in rat femoral artery. In this regard, a previous study demonstrated a cross-talk between &#946;-adrenergic receptor and 5-HT1 on glutamate release in cerebrocortical nerve terminals<sup>26</sup>. Thus, our data reinforce that the proximal segment of the femoral artery is an interesting vascular tissue to study 5-HT receptors and its complex signaling pathway. However, we cannot ascertain from this study which 5-HT receptor subtype is mediating the contractile response and/or which transduction effectors are contributing to the suppression of the &#946;-adrenergic receptor-mediating relaxation in rat femoral artery. Evidence has shown that the 5-HT1 receptors family is mostly linked to Gi/o, which are pertussis toxin sensitive and negatively coupled with adenylyl cyclase<sup>9</sup>. On the other hand, &#946;-adrenergic receptor activation is coupled to Gs protein which in turn leads to the activation of cAMP/PKA signaling pathway in the cardiovascular system<sup>19</sup>. Thus, the antagonistic cross-talk between 5-HT receptors and &#946;-adrenergic receptor could be occurring at G-protein-coupled receptor as well as at the level of PKA substrates since forskolin partially restored the suppression of the &#946;-adrenergic receptor-mediating relaxation in 5-HT-precontracted rat femoral artery ring. The functional significance of these data may be related to the incidence of vascular disease and 5-HT agonists/5-HT uptake blockers administration in some disorders such migraine and obesity.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>In conclusion, our data showed clearly that an interaction between &#946; adrenergic- and serotonergic- receptors signaling pathway occurs in rat femoral artery rings. Moreover, this study provides an interesting perspective to study serotoninergic receptor signaling pathway under normal and pathological conditions in an attempt to improve the clinical outcomes in patients with PAD.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Interacci&#243;n entre las v&#237;as de se&#241;alizaci&#243;n de receptores serotonin&#233;rgicos y &#946;-adren&#233;gicos en la arteria femoral de ratones</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: La enfermedad coronaria ha sido ampliamente estudiada en las investigaciones cardiovasculares. Sin embargo, los pacientes con enfermedad arterial perif&#233;rica (EAP), tienen los peores resultados en comparaci&#243;n con aquellos con la enfermedad arterial coronaria. Por tanto, los estudios farmacol&#243;gicos con la arteria femoral son extremadamente importantes para obtener una mejor comprensi&#243;n de las respuestas cl&#237;nicas y fisiopatol&#243;gicas de la EAP. OBJETIVO: Evaluar las propiedades farmacol&#243;gicas de los agentes contr&#225;ctiles y relajantes en la arteria femoral de los ratones. M&#201;TODOS: Las curvas de concentraci&#243;n-respuesta a los agentes conctr&#225;ctiles fenilefrina (FE) y a la serotonina (5-HT) y los agentes relajantes isoproterenol (ISO) y forskolina, se obtuvieron en la arteria femoral de ratones ya aislada. Para las respuestas a la relajaci&#243;n, los tejidos fueron contra&#237;dos con FE o 5-HT. RESULTADOS: La potencia de clasificaci&#243;n en la arteria femoral fue de 5-HT &gt; FE para las respuestas contr&#225;ctiles. En los tejidos contra&#237;dos con 5-HT, las respuestas de relajaci&#243;n al isoproterenol fueron pr&#225;cticamente eliminadas en comparaci&#243;n con los tejidos contra&#237;dos con FE. La forskolina, un estimulante de la adenilil ciclasa, restaur&#243; parcialmente la respuesta de relajaci&#243;n al ISO en los tejidos contra&#237;dos con 5-HT. CONCLUSI&#211;N: Ocurre una interacci&#243;n entre las v&#237;as de se&#241;alizaci&#243;n de los receptores &#946;-adren&#233;rgicos y serotonin&#233;rgicos en la arteria femoral. Adem&#225;s, esa investigaci&#243;n suministra un nuevo modelo para estudiar las v&#237;as de se&#241;alizaci&#243;n serotonin&#233;rgicas en condiciones normales y patol&#243;gicas que puedan ayudar a comprender los resultados cl&#237;nicos en la EAP.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Enfermedad arterial perif&#233;rica</kwd>
        <kwd>receptores adren&#233;rgicos</kwd>
        <kwd>receptores adren&#233;rgicos</kwd>
        <kwd>receptores de serotonina</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="enda-body3">
          <label>
            <bold>Interacci&#243;n entre las v&#237;as de se&#241;alizaci&#243;n de receptores serotonin&#233;rgicos y </bold>
          </label>
          <p>
            <bold>&#946;</bold>
          </p>
          <p>
            <bold>-adren&#233;gicos en la arteria femoral de ratones</bold>
          </p>
        </fn>
      </p>
      <p>
        <bold>Maria Andr&#233;ia Delbin<sup>I</sup>; Alexandre S&#233;rgio Silva<sup>I</sup>; Edson Antunes<sup>II</sup>; Angelina Zanesco<sup>I</sup></bold>
      </p>
      <p><sup>I</sup>Universidade Estadual Paulista J&#250;lio de Mesquita Filho (UNESP), S&#227;o Paulo, SP </p>
      <p><sup>II</sup>Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> La enfermedad coronaria ha sido ampliamente estudiada en las investigaciones cardiovasculares. Sin embargo, los pacientes con enfermedad arterial perif&#233;rica (EAP), tienen los peores resultados en comparaci&#243;n con aquellos con la enfermedad arterial coronaria. Por tanto, los estudios farmacol&#243;gicos con la arteria femoral son extremadamente importantes para obtener una mejor comprensi&#243;n de las respuestas cl&#237;nicas y fisiopatol&#243;gicas de la EAP.</p>
      <p><bold>OBJETIVO:</bold> Evaluar las propiedades farmacol&#243;gicas de los agentes contr&#225;ctiles y relajantes en la arteria femoral de los ratones.</p>
      <p><bold>M&#201;TODOS:</bold> Las curvas de concentraci&#243;n-respuesta a los agentes conctr&#225;ctiles fenilefrina (FE) y a la serotonina (5-HT) y los agentes relajantes isoproterenol (ISO) y forskolina, se obtuvieron en la arteria femoral de ratones ya aislada. Para las respuestas a la relajaci&#243;n, los tejidos fueron contra&#237;dos con FE o 5-HT.</p>
      <p><bold>RESULTADOS:</bold> La potencia de clasificaci&#243;n en la arteria femoral fue de 5-HT &gt; FE para las respuestas contr&#225;ctiles. En los tejidos contra&#237;dos con 5-HT, las respuestas de relajaci&#243;n al isoproterenol fueron pr&#225;cticamente eliminadas en comparaci&#243;n con los tejidos contra&#237;dos con FE. La forskolina, un estimulante de la adenilil ciclasa, restaur&#243; parcialmente la respuesta de relajaci&#243;n al ISO en los tejidos contra&#237;dos con 5-HT.</p>
      <p><bold>CONCLUSI&#211;N:</bold> Ocurre una interacci&#243;n entre las v&#237;as de se&#241;alizaci&#243;n de los receptores &#946;-adren&#233;rgicos y serotonin&#233;rgicos en la arteria femoral. Adem&#225;s, esa investigaci&#243;n suministra un nuevo modelo para estudiar las v&#237;as de se&#241;alizaci&#243;n serotonin&#233;rgicas en condiciones normales y patol&#243;gicas que puedan ayudar a comprender los resultados cl&#237;nicos en la EAP.</p>
      <p><bold>Palabras clave:</bold> Enfermedad arterial perif&#233;rica, arteria femoral/fisiopatolog&#237;a, receptores adren&#233;rgicos/alfa, receptores adren&#233;rgicos/beta, receptores de serotonina.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>Una importante rama de la arteria il&#237;aca, la arteria femoral, irriga los m&#250;sculos de los miembros inferiores y los tejidos perif&#233;ricos, siendo un vaso sangu&#237;neo &#250;nico, con una conducci&#243;n larga, de alta resistencia de flujo y con una fuerte relevancia para las intervenciones m&#233;dicas<sup>1</sup>. De hecho, aproximadamente un 50% de las enfermedades arteriales oclusivas (EAO) ocurren en la arteria femoral, pudiendo conllevar a una claudicaci&#243;n intermitente y a una isquemia cr&#237;tica del miembro, con un da&#241;o significativo para las actividades diarias de los pacientes<sup>2</sup>. El aparecimiento de la enfermedad arterial perif&#233;rica (EAP), ha aumentado en la poblaci&#243;n mundial y se han hecho ostensibles esfuerzos para intentar mejorar las consecuencias no favorables de la intervenci&#243;n m&#233;dica en el tratamiento a largo plazo. Adem&#225;s de eso, factores como el tabaquismo, la dislipidemia, la diabetes mellitus, la arteriosclerosis y la edad avanzada, han sido involucrados en la patog&#233;nesis de la EAP<sup>3,4</sup>. Aunque la mayor&#237;a de las investigaciones cardiovasculares se haya concentrado en la enfermedad coronaria, tales como los avances en las intervenciones quir&#250;rgicas y el descubrimiento de nuevas terapias farmacol&#243;gicas, los pacientes con EAP gozan de los peores resultados en comparaci&#243;n con aquellos con la enfermedad de la arteria coronaria<sup>5</sup>. Por esa raz&#243;n, los estudios farmacol&#243;gicos con la arteria femoral son muy importantes para obtener una mejor comprensi&#243;n de las respuestas cl&#237;nicas y fisiopatol&#243;gicas de la EAP.</p>
      <p>Sabemos que la serotonina (5-hidroxitriptamina, 5-HT) desempe&#241;a funciones biol&#243;gicas importantes en el sistema cardiovascular, incluyendo la agregaci&#243;n plaquetaria, bradicardia o la taquicardia, hipotensi&#243;n o la hipertensi&#243;n y la vasodilataci&#243;n o la vasoconstrici&#243;n<sup>6,7</sup>. La diversidad de las acciones funcionales de la 5-HT se relaciona con el n&#250;mero de subtipos de receptores, como tambi&#233;n con la complejidad de la v&#237;a de se&#241;alizaci&#243;n que est&#225; involucrada en las respuestas. En ese sentido, por lo menos 15 subtipos de receptores 5-HT han sido caracterizados, que a su vez se subdividen en siete familias de receptores, de acuerdo con las propiedades farmacol&#243;gicas, las secuencias de amino&#225;cidos, la organizaci&#243;n de los genes y las v&#237;as de acoplamiento del segundo mensajero<sup>8,9</sup>. Las familias de receptores 5-HT1<sub>1</sub>, 5-HT<sub>2</sub>, 5-HT<sub>4</sub>, 5-HT<sub>5</sub>, 5-HT<sub>6</sub> y 5-HT<sub>7</sub> se acoplan a las G-prote&#237;nas, mientras que los receptores 5-HT<sub>3</sub> son canales i&#243;nicos asociados a la 5-HT. Entre los receptores 5-HT, los subtipos 5-HT<sub>1</sub> y 5-HT<sub>2</sub> realizan un papel importante en la regulaci&#243;n del sistema cardiovascular, en que la familia del receptor 5-HT<sub>1</sub> est&#225; ligada principalmente a la prote&#237;na G inhibitoria (Gi/o), que impide la formaci&#243;n de la adenosina monofosfato c&#237;clico (AMPc), mientras que la familia de receptores 5-HT2 est&#225; acoplada preferentemente a las prote&#237;nas Gq/11, conllevando a la activaci&#243;n de la v&#237;a de se&#241;alizaci&#243;n IP3/PKC/citos&#243;lica [Ca<sup>2+</sup>]<sup>10</sup>. Tanto la familia del receptor 5-HT<sub>1</sub> como la de 5-HT<sub>2</sub> se asocian a la contracci&#243;n del m&#250;sculo liso vascular y a la formaci&#243;n del trombo<sup>9,11</sup>.</p>
      <p>La activaci&#243;n de los receptores &#945;- y &#946;-adren&#233;rgicos por catecolaminas tambi&#233;n produce una serie de respuestas funcionales en el sistema cardiovascular, incluyendo las respuestas cronotr&#243;picas positivas y el control del tono vascular<sup>12,13</sup>. La vasoconstricci&#243;n mediada por el receptor &#945;-adren&#233;rgico, ha sido ampliamente estudiada en las condiciones normales y patol&#243;gicas<sup>14-16</sup>, pero pocos estudios eval&#250;an la vasodilataci&#243;n mediada por los receptores &#946;-adren&#233;rgicos<sup>17,18</sup>. En ese sentido, por lo menos tres subtipos de receptores &#946;-adren&#233;rgicos median las respuestas de relajaci&#243;n en los tejidos vasculares y se acoplan a la prote&#237;na Gs, conllevando a la activaci&#243;n de la v&#237;a de se&#241;alizaci&#243;n de la prote&#237;na quinasa (PK) dependiente de AMPc<sup>19</sup>.</p>
      <p>Las v&#237;as de se&#241;alizaci&#243;n de los receptores serotonin&#233;rgicos o adren&#233;rgicos son dianas para el tratamiento de las enfermedades cardiovasculares, incluyendo la insuficiencia card&#237;aca, la hipertensi&#243;n arterial, la enfermedad coronaria y la EAP<sup>4,20</sup>. As&#237;, los estudios farmacol&#243;gicos sobre peque&#241;as arterias y las interacciones entre los f&#225;rmacos, involucrando las v&#237;as de se&#241;alizaci&#243;n de los receptores serotonin&#233;rgicos y adren&#233;rgicos, son cruciales para el desarrollo de nuevos compuestos en un intento de mejorar la calidad de vida de los pacientes con enfermedades vasculares. Por tanto, el objetivo de este estudio fue evaluar las propiedades farmacol&#243;gicas de los agentes contr&#225;ctiles (5-HT y fenilefrina) y los relajantes (isoproterenol y forskolina), en el segmento proximal de la arteria femoral de los ratones.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>Este estudio fue aprobado por el Comit&#233; de &#201;tica de la <italic>Faculdade de Medicina </italic>de la <italic>Universidade de Campinas </italic>(UNICAMP), bajo el N&#186; de protocolo 1307-1.</p>
      <p>
        <bold>Animales</bold>
      </p>
      <p>Ratones Wistar machos (407, 6g) que se alojaron individualmente en 26 &#177; 2 &#186;C, con alimentos y agua <italic>ad libitum</italic> (a su gusto), y en 12h de luz (ciclo oscuro y con las luces encendidas a las 6h). Adem&#225;s, se sometieron a la inhalaci&#243;n de CO<sub>2</sub>, y fueron sacrificados por decapitaci&#243;n y sangrados.</p>
      <p>
        <bold>Anillos aislados de la arteria femoral de ratones</bold>
      </p>
      <p>La arteria femoral fue r&#225;pidamente retirada y puesta en una soluci&#243;n tamp&#243;n de Krebs-Henseleit, refrigerada con la siguiente composici&#243;n (mM): NaCl 118, KCl 4.7, KH<sub>2</sub>PO<sub>4</sub> 1.2, MgSO<sub>4</sub>.7H<sub>2</sub>O 1.17, CaCl<sub>2</sub>.2H<sub>2</sub>O 2.5, NaHCO<sub>3</sub> 25 y glucosa 5.6. El segmento proximal de la arteria femoral se aisl&#243;, y dos anillos (de aproximadamente 2 mm de largura), fueron retirados y montados en una c&#225;mara de &#243;rganos de 5 ml. Un mi&#243;grafo para la grabaci&#243;n de la fuerza isom&#233;trica (Danish Myo Technology, modelo 610m, Aarthus N, Dinamarca), se acopl&#243; a un sistema de adquisici&#243;n, con el <italic>software</italic> espec&#237;fico (PowerLab 30/08, LabChart 7, ADInstruments, Sydney-NSW, Australia). La soluci&#243;n de ba&#241;o se mantuvo a 37&#186;C y fue continuamente gasificada con un 95%-O<sub>2</sub> y un 5%-CO<sub>2</sub>, y con un pH de 7,4. Los tejidos fueron estabilizados por 60 minutos, bajo una tensi&#243;n de reposo de 1 mN<sup>21</sup>.</p>
      <p>
        <bold>Curvas concentraci&#243;n-respuesta a los agentes contr&#225;ctiles</bold>
      </p>
      <p>Posteriormente al per&#237;odo de equilibrio, los anillos fueron contra&#237;dos con KCl 80 mM, para verificar la viabilidad del tejido y fueron lavados con Krebs. Adem&#225;s de eso, fueron contra&#237;dos con fenilefrina (FE, 1 mM) y relajados con acetilcolina (ACH, 1 <italic>&#181;</italic>M), para confirmar la integridad del endotelio. Los anillos sin respuestas contr&#225;ctiles o relajantes se eliminaron.</p>
      <p>Con el fin de evaluar las respuestas contr&#225;ctiles mediadas por los receptores serotonin&#233;rgicos y &#945;-adren&#233;rgicos, las curvas acumulativas concentraci&#243;n-respuesta a la 5-hidroxitriptamina (5-HT: 1 nM - 100 mM) y a la fenilefrina (FE: 1 nM - 100 mM), fueron construidas en el segmento proximal de los anillos de la arteria femoral<sup>22</sup>.</p>
      <p>Las curvas concentraci&#243;n-respuesta al isoproterenol (1 nM - 10 mM) se obtuvieron en los tejidos contra&#237;dos con FE (1 mM) o con 5-HT (10 mM), para analizar la interacci&#243;n entre la activaci&#243;n de los receptores b-adren&#233;rgicos y la de los receptores &#945;-adren&#233;rgicos o serotonin&#233;rgicos. Tambi&#233;n realizamos curvas concentraci&#243;n-respuesta para el activador adenilato ciclasa y la forskolina (1 nM - 100 <italic>&#181;</italic>M), en los anillos femorales, con el fin de determinar si las interacciones medicamentosas pueden darse en el nivel del receptor o en los niveles superiores.</p>
      <p>Todos los datos de concentraci&#243;n-respuesta fueron evaluados para ajustarlos en una funci&#243;n log&#237;stica con la f&#243;rmula: E = Emax/((1 + (10<sup>c</sup>/10<sup>x</sup>)<sup>n</sup>) + F), en que E es el efecto del basal por encima; Emax es la respuesta m&#225;xima producida por el agonista; c es el logaritmo de la EC<sub>50</sub>, concentraci&#243;n del agonista que produce la mitad del m&#225;ximo de respuesta; x es el logaritmo de la concentraci&#243;n del agonista; n es un par&#225;metro de ajuste de curvas que define la inclinaci&#243;n de la l&#237;nea de respuesta de concentraci&#243;n; y F es la respuesta observada en ausencia del agonista a&#241;adido. El an&#225;lisis de regresi&#243;n no lineal fue utilizado para determinar los par&#225;metros Emax y log EC<sub>50</sub>, utilizando GraphPad Prism (GraphPad Software Inc., San Diego, CA), con la restricci&#243;n de que F = 0. Las respuestas para cada agonista quedan demostradas como el promedio &#177; EPM de potencia (pEC50) y respuesta m&#225;xima (Emax). Las relajaciones fueron plotadas como porcentajes de las contracciones inducidas por la FE o 5-HT, y las respuestas contr&#225;ctiles fueron plotadas como porcentaje de la concentraci&#243;n inducida por KCl (80 mM).</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Los datos est&#225;n expresados como promedio &#177; EPM de experimentos <italic>n</italic>. El test <italic>t</italic> de Student pareado o no pareado, se hizo por medio de un <italic>software</italic> espec&#237;fico (InStat, GraphPad Software, La Jolla, CA, EUA). Los valores de <italic>p</italic> inferiores a 0,05 fueron considerados como estad&#237;sticamente significativos.</p>
      <p>
        <bold>F&#225;rmacos</bold>
      </p>
      <p>El cloruro de acetilcolina, hidrocloruro de fenilefrina, 5-hidroxitriptamina, forskolina y el isoproterenol, se adquirieron por Sigma Chemical Co. (St Louis, MO, EUA).</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>
        <bold>Respuestas contr&#225;ctiles</bold>
      </p>
      <p>Tanto la 5-HT como la FE generaron respuestas contr&#225;ctiles dependientes de la concentraci&#243;n en anillos de arteria femoral (<xref ref-type="fig" rid="es_a06fig01-body3">Figura 1A</xref>). La potencia de la 5-HT fue significativamente mayor en comparaci&#243;n con la FE agonista-&#945;1 (cerca de 20 veces), en el segmento proximal de la arteria femoral de ratones. No fueron encontradas diferencias en las respuestas m&#225;ximas para ambos agonistas. Esos datos aparecen resumidos en la <xref ref-type="table" rid="es_a06tab01m-body3">Tabla 1</xref>.</p>
      <p content-type="asset">
        <table-wrap id="es_a06tab01m-body3">
          <graphic xlink:href="1678-4170-abc-98-01-0029-00121-gt01-es.jpg"/></table-wrap>
      </p>
      <p content-type="html"><fig id="es_a06fig01-body3"><graphic xlink:href="https://minio.scielo.br/documentstore/1678-4170/FsHtbKLhsmB5XxnMnxRcS5b/aae7cbb97999a372a06de1988d258a65fc69cece.jpg"/><graphic xlink:href="https://minio.scielo.br/documentstore/1678-4170/FsHtbKLhsmB5XxnMnxRcS5b/a249a4e7731d83fbf9b4180e28b4996739b22456.jpg"/><graphic xlink:href="1678-4170-abc-98-01-0029-00121-gf01-es.jpg"/></fig>&#13;
&#160;&#13;
</p>
      <p>
        <bold>Respuestas de relajaci&#243;n</bold>
      </p>
      <p>En otro conjunto de experimentos, evaluamos las respuestas de relajaci&#243;n para el isoproterenol agonista &#946;-adren&#233;rgico, en que los anillos de la arteria femoral fueron contra&#237;dos con FE (10 <italic>&#181;</italic>M) o 5-HT (1 <italic>&#181;</italic>M). En los anillos contra&#237;dos con FE, el isoproterenol produjo respuestas de relajaci&#243;n dependientes de la concentraci&#243;n. Sin embargo, en los anillos contra&#237;dos con 5-HT, el isoproterenol indic&#243; una respuesta de relajaci&#243;n inferior en los anillos de la arteria femoral con relaci&#243;n a los anillos pareados contra&#237;dos con FE (<xref ref-type="fig" rid="es_a06fig01-body3">Figura 1B</xref>). Para comprobar la hip&#243;tesis de que los tejidos contra&#237;dos con 5-HT afectaban el nivel de los receptores &#946;-adren&#233;rgicos o los nieles superiores (v&#237;a de se&#241;alizaci&#243;n), curvas de concentraci&#243;n-respuesta para el activador de la adenilil ciclasa forskolina se obtuvieron en los anillos de la arteria femoral contra&#237;dos con FE (10 <italic>&#181;</italic>M) o 5-HT (1 <italic>&#181;</italic>M). En los anillos contra&#237;dos con FE, la forskolina produjo respuestas de relajaci&#243;n dependientes de la concentraci&#243;n. Sin embargo, un desplazamiento paralelo dextral, de aproximadamente nueve veces, fue observado en las curvas de concentraci&#243;n-respuesta para la forskolina en tejidos contra&#237;dos con 5-HT, en comparaci&#243;n con los anillos pareados de la arteria femoral contra&#237;dos con FE (<xref ref-type="fig" rid="es_a06fig01-body3">Figura 1C</xref>). No se encontraron diferencias en las respuestas m&#225;ximas para el activador de la adenilil ciclasa en contracci&#243;n con dos agentes. Esos datos est&#225;n resumidos en la <xref ref-type="table" rid="es_a06tab01m-body3">Tabla 1</xref>.</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>En este estudio pudimos observar, que la potencia de orden de clasificaci&#243;n en el segmento proximal de la arteria femoral fue de 5-HT &gt; FE, para las respuestas contr&#225;ctiles pudiendo reflejar una mayor densidad de los receptores serotonin&#233;rgicos o una elevada eficacia del mecanismo de v&#237;a de se&#241;alizaci&#243;n en esa preparaci&#243;n, en contraste con la v&#237;a descendente de receptores &#945;-adren&#233;rgicos/AMPc/PK. Curiosamente, un estudio anterior encontr&#243; una potencia de clasificaci&#243;n similar para la 5-HT en diferentes anillos arteriales, incluyendo los anillos mesent&#233;ricos, caudales y basilares<sup>23</sup>. Adem&#225;s, la potencia de 5-HT encontrada en nuestro estudio para el segmento proximal en la arteria femoral (6,86) estuvo &#237;ntimamente relacionada con los resultados obtenidos en la arteria basilar (6,88), indicando que ambas preparaciones presentan grandes similitudes en las propiedades farmacol&#243;gicas. Adem&#225;s, las evidencias cl&#237;nicas demuestran que la EAP es m&#225;s com&#250;n en los pacientes con jaqueca que en los pacientes no afectados por la cefalea<sup>24,25</sup>. En su totalidad, nuestros datos demuestran que la arteria femoral es un interesante modelo para el estudio de las v&#237;as de se&#241;alizaci&#243;n de los receptores serotonin&#233;rgicos en condiciones normales y patol&#243;gicas, como diabetes mellitus y la arteriosclerosis.</p>
      <p>En este estudio, tambi&#233;n descubrimos que los tejidos contra&#237;dos con 5-HT pr&#225;cticamente eliminaron la respuesta de relajaci&#243;n para el isoproterenol (10% de respuestas m&#225;ximas), habiendo sido parcialmente restaurados por la forskolina, como estimulante de acci&#243;n directa de la guanilato ciclasa que ignora a los &#946;-adren&#233;rgicos. Por tanto, nuestros resultados demuestran una interacci&#243;n entre las v&#237;as de se&#241;alizaci&#243;n de los receptores b-adren&#233;rgicos y serotonin&#233;rgicos en la arteria femoral. En ese sentido, un estudio anterior arroj&#243; una interacci&#243;n entre el receptor &#946;-adren&#233;rgico y la 5-HT<sub>1</sub> en la liberaci&#243;n de glutamato en los terminales del nervio cerebrocortical<sup>26</sup>. Por lo tanto, nuestros datos refuerzan el postulado de que el segmento proximal de la arteria femoral es un tejido vascular interesante para estudiar a los receptores de 5-HT y la compleja v&#237;a de se&#241;alizaci&#243;n. Sin embargo, no podemos determinar, a partir de este estudio, que el subtipo de receptor 5-HT media la respuesta contr&#225;ctil o los efectores de transducci&#243;n que contribuyen para la supresi&#243;n de la relajaci&#243;n de mediaci&#243;n del receptor &#946;-adren&#233;rgico en la arteria femoral de ratones. Algunas evidencias nos indican que la familia de receptores 5-HT1 est&#225; fundamentalmente vinculada a la Gi/o, prote&#237;na sensible a la toxina pertussis y negativamente asociada a la adenilil ciclasa<sup>9</sup>. Por otro lado, la activaci&#243;n del receptor &#946;-adren&#233;rgico est&#225; acoplada a la prote&#237;na Gs que, a su vez, conlleva a la activaci&#243;n de la v&#237;a de se&#241;alizaci&#243;n AMPc/PK en el sistema cardiovascular<sup>19</sup>. Por tanto, la interacci&#243;n antag&#243;nica entre los receptores 5-HT y &#946;-adren&#233;rgicos, puede darse en el receptor acoplado a la prote&#237;na G, como tambi&#233;n en el nivel de los sustratos de PK, teniendo en cuenta que la forskolina restaur&#243; parcialmente la supresi&#243;n de la relajaci&#243;n de mediaci&#243;n del receptor &#946;-adren&#233;rgico en los anillos de la arteria femoral de ratones contra&#237;dos con 5-HT. El significado funcional de esos datos puede estar relacionado con el aparecimiento de la enfermedad vascular y de la administraci&#243;n de agonistas de 5-HT/bloqueadores de captaci&#243;n de 5-HT en algunas enfermedades como la jaqueca y la obesidad.</p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>Como conclusi&#243;n, nuestros datos revelaron claramente que ocurre una interacci&#243;n entre las v&#237;as de se&#241;alizaci&#243;n de los receptores b-adren&#233;rgicos y serotonin&#233;rgicos en los anillos de la arteria femoral de ratones. Adem&#225;s, este estudio suministra una perspectiva interesante para el estudio de las v&#237;as de se&#241;alizaci&#243;n de los receptores serotonin&#233;rgicos en condiciones normales y patol&#243;gicas, en un intento de mejorar los resultados cl&#237;nicos en pacientes con EAP.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>FAPESP financi&#243; el presente estudio.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de tesis de Doctorado de Alexandre S&#233;rgio Silva, por Universidade Estadual Paulista J&#250;lio de Mesquita Filho e Universidade Estadual de Campinas.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
